BACKGROUND: Nicotine receptor partial agonists may help smokers to quit by a combination of maintaining moderate levels of dopamine to counteract withdrawal symptoms (acting as an agonist) and reducing smoking satisfaction (acting as an antagonist). Varenicline was developed as a nicotine receptor partial agonist from cytisine, a drug widely used in central and eastern Europe for smoking cessation. The first trial reports of varenicline were released in 2006, and further trials are underway....Expand abstract
- Publication status:
- Publisher copy:
- Copyright date:
Nicotine receptor partial agonists for smoking cessation.
If you are the owner of this record, you can report an update to it here: Report update to this record